Overview

FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease

Status:
Not yet recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
FGF-1 for the treatment of patients with peripheral arterial disease with intermittent claudication.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
CardioVascular BioTherapeutics, Inc.